

# TDN345

**Catalog No: tcsc6829**



## Available Sizes

**Size:** 1mg

**Size:** 5mg

**Size:** 10mg

**Size:** 20mg



## Specifications

**CAS No:**

134069-68-4

**Formula:**

$C_{28}H_{34}F_2N_2O_2$

**Pathway:**

Membrane Transporter/Ion Channel

**Target:**

Calcium Channel

**Purity / Grade:**

>98%

**Solubility:**

10 mM in DMSO

**Observed Molecular Weight:**


468.58

## Product Description

TDN345 is a **Ca<sup>2+</sup>** antagonist, used for the treatment of vascular and senile dementia including Alzheimer's disease.

**In Vitro:** TDN-345 (10  $\mu$ M) significantly increases the intracellular NGF content in the time-course study. TDN-345 induces NGF synthesis/secretion at the concentrations of 0.1  $\mu$ M; statistically significant at 1  $\mu$ M. The ED<sub>50</sub> is 0.88  $\mu$ M<sup>[1]</sup>.

**In Vivo:** TDN-345 (0.1-1.0 mg/kg, p.o.) dose-dependently decreases the mortality and ischemic neurological deficit score when administered orally twice, 60 min before ischemia and 90 min after recirculation. Additionally, TDN-345 (0.2 or 1.0 mg/kg, p.o. once daily for 3 weeks after the onset of stroke) decreases the mortality and recurrence of stroke in SHRSP<sup>[2]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!